Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Imidazo[1,5-a]pyrazines: orally efficacious inhibitors of mTORC1 and mTORC2.
Crew AP, Bhagwat SV, Dong H, Bittner MA, Chan A, Chen X, Coate H, Cooke A, Gokhale PC, Honda A, Jin M, Kahler J, Mantis C, Mulvihill MJ, Tavares-Greco PA, Volk B, Wang J, Werner DS, Arnold LD, Pachter JA, Wild R, Gibson NW. Crew AP, et al. Among authors: arnold ld. Bioorg Med Chem Lett. 2011 Apr 1;21(7):2092-7. doi: 10.1016/j.bmcl.2011.01.139. Epub 2011 Feb 3. Bioorg Med Chem Lett. 2011. PMID: 21353551
Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.
Dai Y, Guo Y, Frey RR, Ji Z, Curtin ML, Ahmed AA, Albert DH, Arnold L, Arries SS, Barlozzari T, Bauch JL, Bouska JJ, Bousquet PF, Cunha GA, Glaser KB, Guo J, Li J, Marcotte PA, Marsh KC, Moskey MD, Pease LJ, Stewart KD, Stoll VS, Tapang P, Wishart N, Davidsen SK, Michaelides MR. Dai Y, et al. J Med Chem. 2005 Sep 22;48(19):6066-83. doi: 10.1021/jm050458h. J Med Chem. 2005. PMID: 16162008
OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models.
Garton AJ, Crew AP, Franklin M, Cooke AR, Wynne GM, Castaldo L, Kahler J, Winski SL, Franks A, Brown EN, Bittner MA, Keily JF, Briner P, Hidden C, Srebernak MC, Pirrit C, O'Connor M, Chan A, Vulevic B, Henninger D, Hart K, Sennello R, Li AH, Zhang T, Richardson F, Emerson DL, Castelhano AL, Arnold LD, Gibson NW. Garton AJ, et al. Among authors: arnold ld. Cancer Res. 2006 Jan 15;66(2):1015-24. doi: 10.1158/0008-5472.CAN-05-2873. Cancer Res. 2006. PMID: 16424037 Free article.
1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channel.
Dinges J, Albert DH, Arnold LD, Ashworth KL, Akritopoulou-Zanze I, Bousquet PF, Bouska JJ, Cunha GA, Davidsen SK, Diaz GJ, Djuric SW, Gasiecki AF, Gintant GA, Gracias VJ, Harris CM, Houseman KA, Hutchins CW, Johnson EF, Li H, Marcotte PA, Martin RL, Michaelides MR, Nyein M, Sowin TJ, Su Z, Tapang PH, Xia Z, Zhang HQ. Dinges J, et al. Among authors: arnold ld. J Med Chem. 2007 May 3;50(9):2011-29. doi: 10.1021/jm061223o. Epub 2007 Apr 11. J Med Chem. 2007. PMID: 17425296
A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.
Ji QS, Mulvihill MJ, Rosenfeld-Franklin M, Cooke A, Feng L, Mak G, O'Connor M, Yao Y, Pirritt C, Buck E, Eyzaguirre A, Arnold LD, Gibson NW, Pachter JA. Ji QS, et al. Among authors: arnold ld. Mol Cancer Ther. 2007 Aug;6(8):2158-67. doi: 10.1158/1535-7163.MCT-07-0070. Epub 2007 Aug 1. Mol Cancer Ther. 2007. PMID: 17671083
Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.
Bhagwat SV, Gokhale PC, Crew AP, Cooke A, Yao Y, Mantis C, Kahler J, Workman J, Bittner M, Dudkin L, Epstein DM, Gibson NW, Wild R, Arnold LD, Houghton PJ, Pachter JA. Bhagwat SV, et al. Among authors: arnold ld. Mol Cancer Ther. 2011 Aug;10(8):1394-406. doi: 10.1158/1535-7163.MCT-10-1099. Epub 2011 Jun 14. Mol Cancer Ther. 2011. PMID: 21673091
Target-Directed Self-Assembly of Homodimeric Drugs Against β-Tryptase.
Giardina SF, Werner DS, Pingle M, Foreman KW, Bergstrom DE, Arnold LD, Barany F. Giardina SF, et al. Among authors: arnold ld. ACS Med Chem Lett. 2018 Jul 5;9(8):827-831. doi: 10.1021/acsmedchemlett.8b00204. eCollection 2018 Aug 9. ACS Med Chem Lett. 2018. PMID: 30128075 Free PMC article.
Novel, Self-Assembling Dimeric Inhibitors of Human β Tryptase.
Giardina SF, Werner DS, Pingle M, Feinberg PB, Foreman KW, Bergstrom DE, Arnold LD, Barany F. Giardina SF, et al. Among authors: arnold ld. J Med Chem. 2020 Mar 26;63(6):3004-3027. doi: 10.1021/acs.jmedchem.9b01689. Epub 2020 Feb 27. J Med Chem. 2020. PMID: 32057241
119 results